MBO for Vickers Laboratories
Current members of management team buy firm from major shareholder
Three members of the company’s current management team – Steve Foster, operations director; Phil Constantine, operations manager; and Paul Bottomley, quality and supply chain manager – have acquired the business from the current majority shareholder, Julian Driver. They aim to grow the business by finding new product niches.
Driver has been involved with the firm since 1976 and now wants to take some time off to pursue other interests.
Since 2003 profit levels have increased by more than 20%. Current turnover is £2.25m.
The new management team emphasises that it is ‘business as usual but with some changes’ for the Pudsey based business, which employs 22 people.
All three participants in the MBO have been with the company for more than 20 years and have played a major part in its success.
Foster, the new managing director, joined Vickers in 1987 as a laboratory chemist. He then moved into products and services, launching the customer service team, before taking over operations in 2002.
Bottomley, sales director in the new team, joined Vickers in 1983 and progressed through operations and administration before becoming the company’s buyer and then supply chain manager. He has recently implemented a joint venture in Asia and has managed the quality system to achieve ISO 9001-2008.
Constantine, the new operations director, joined the company in 1981. Starting as a process operator, he became operations manager in 2007.
‘It is very exciting and fulfilling on a personal level to see the team I have worked with and mentored over many years become the new owners of the business,’ said Driver.
Vickers currently operates on four key areas: laboratory reagents; specialised monomers for use in the contact lens and medical industries; precision solutions and liquids for industry; and online monitoring for the water industry.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From bespoke to scalable: closing the manufacturing gap in advanced therapeutics
Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing
Piramal Pharma Solutions announces partnership with Botanix to support drug substance development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Manufacturing
ProtaGene and Merck partner to deliver end-to-end biologics testing
The duo will combine ProtaGene's early-stage biologics expertise with Merck's BioReliance GMP testing infrastructure, offering biopharmaceutical customers an integrated testing solution across the full drug development lifecycle